| ABSTRACT Objective:To systematically evaluate the clinical effectiveness and safety of compound Kushen injection combined with transcatheter hepatic arterial chemoembolization (TACE) chemotherapy in the treatment of liver carcinoma. Methods:Randomized controlled trials(RCTs) regarding compound Kushen injection treating liver carcinoma were searched in PubMed, the Cochrane library, Embase, CNKI, SinoMed, VIP, and Wanfang databases from establishment to October 2016. Two researchers independently identified and evaluated the methodological quality of the included RCTs, then the data were extracted and Meta analyzed by RevMan 5.3 software.Results:A total of 11 RCTs involving 875 participants were included. In the Meta analysis, compound Kushen injection combined with TACE chemotherapy can be better than TACE chemotherapy regimen alone in the treatment of liver carcinoma in respect of improvement in the total effective rate (RR=1.35, 95%CI: 1.18 1.53, P<0.000 01), improvement in life quality (RR=1.28, 95%CI: 1.10 1.47, P=0.001). In addition, compound Kushen injection can reduce the incidence rate of adverse reactions.Conclusion: Thus, our study showed that compound Kushen injection combined with TACE chemotherapy regimen is beneficial in the treatment of liver carcinoma, while our conclusion should be confirmed by more well designed and large scale RCTs. |
